Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk of peripheral neuropathy is already in labeling and FDA doesn’t want to require a black box, illustrating the agency’s ongoing challenge to fully communicate risks without unduly limiting access or use.